Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer
International Journal of Radiation Oncology*Biology*Physics · 2026
DOI: 10.1016/j.ijrobp.2026.09.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026. Verfasst von I-Wei Ho und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Hematology Oncology, E-Da Cance…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Heavy Ion Radiotherapy, Chemoradiotherapy. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Melissa Lee Cancer Foundation, National Science and Technology Council, Taipei Veterans General Hospital.
Abstract (Originalsprache)
PURPOSE: Carbon-ion radiation therapy (CIRT) provides effective local control for locally advanced pancreatic cancer, but the optimal integration of systemic therapy remains uncertain. We evaluated the associations of concurrent chemotherapy intensity and cumulative systemic therapy exposure with clinical outcomes and explored the prognostic value of metabolic versus morphologic response. METHODS AND MATERIALS: We retrospectively reviewed 96 patients with locally advanced pancreatic cancer treated with CIRT and concurrent systemic therapy. Patients were stratified by concurrent chemotherapy intensity into single-agent, doublet, and triplet groups. An exploratory 7-month landmark analysis with endpoint-specific eligibility evaluated cumulative systemic therapy exposure. In the imaging substudy, metabolic response was defined as ≥50% reduction in maximum standardized uptake value or metabolic inactivation on post-treatment 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) (PET/computed tomography or PET/magnetic resonance imaging). RESULTS: No statistically significant differences in local failure-free survival, distant metastasis-free survival (DMFS), or overall survival (OS) were observed across concurrent chemotherapy intensity groups. In the landmark analysis, standard-duration systemic therapy was not significantly associated with DMFS compared with suboptimal-duration therapy (hazard ratio, 0.68; 95% CI, 0.31-1.50). The adjusted estimate was similar but remained imprecise (hazard ratio, 0.65; 95% CI, 0.29-1.44). In the exploratory imaging substudy, metabolic response was associated with improved local control (P = .013), whereas morphologic response was not. Median OS for the overall cohort was 29.7 months. CONCLUSIONS: Concurrent chemotherapy intensity was not significantly associated with local failure-free survival, DMFS, or OS in this retrospective cohort. Exploratory analyses provided no conclusive evidence that greater cumulative systemic therapy exposure improved clinical outcomes. These findings support prospective evaluation of risk-adapted concurrent systemic therapy during CIRT. 18F-FDG PET metabolic response showed potential prognostic value for local control, supporting its prospective validation as a response biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Department of Hematology Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan; College of Medicine, I-Shou University,…
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Therapeutic and Re…
- Department of Heavy Particles & Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, Taiwan; Department of…
- Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Therapeutic and…
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, Taiwan; Division of Gene…
- School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan; Therapeutic and Research Center of Pancreatic Cancer, Taipei Veterans General Hospital, Taipei, Taiwan; Division of Clin…
Förderung
- Melissa Lee Cancer Foundation
- National Science and Technology Council
- Taipei Veterans General Hospital
Zitieren
APA
Ho, I. W., Lai, I. C., Lin, K. H., Chen, M. H., Hung, Y. P., Shyr, Y. M., Wang, S. E., Li, C. P., Hsu, S. J., Wu, Y. H., Kang, Y. M., Liu, Y. M., Lan, K. L., & Chiang, N. J. (2026). Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2026.09.005
Vancouver
Ho IW, Lai IC, Lin KH, Chen MH, Hung YP, Shyr YM, et al. Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics. 2026. doi:10.1016/j.ijrobp.2026.09.005
BibTeX
@article{Ho2026,
author = {Ho, I-Wei and Lai, I-Chun and Lin, Ko-Han and Chen, Ming-Huang and Hung, Yi-Ping and Shyr, Yi-Ming and Wang, Shin-E and Li, Chung-Pin and Hsu, Shao-Jung and Wu, Yuan-Hung and Kang, Yu-Mei and Liu, Yu-Ming and Lan, Keng-Li and Chiang, Nai-Jung},
title = {Concurrent Systemic Therapy Intensity and Metabolic Response in Carbon-Ion Radiation Therapy for Locally Advanced Pancreatic Cancer},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
doi = {10.1016/j.ijrobp.2026.09.005}
}
EUVIMED